A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human body.
Phase 1
- Conditions
- eurodegenerative disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-506114-49-00
- Lead Sponsor
- Cerevance Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does CVN293 modulate in neurodegenerative disorders, and how does it interact with its primary targets?
How does CVN293's pharmacokinetics compare to standard-of-care treatments for protein aggregation-related neurodegenerative diseases?
What biomarkers are being evaluated in CTIS2023-506114-49-00 to predict future efficacy in Alzheimer's or Parkinson's disease models?
What are the potential adverse events of CVN293 in healthy volunteers, and how does its safety profile align with neuroinflammation-targeting therapies?
What related compounds or combination approaches is Cerevance Inc. developing for neurodegenerative diseases alongside CVN293?